Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma

Respiratory Medicine

Volumn 100, Issue 4, 2006, Pages 586-594

  Ericsson, Karin ^a   Bantje, T A ^b   Huber, R M ^c   Borg, S ^a,d   Bateman, E D ^e  

^a ASTRAZENECA R AND D   (Sweden)

^b AMPHIA HOSPITAL   (Netherlands)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Asthma; Budesonide formoterol; Cost effectiveness; Fluticasone

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; PLACEBO; SALBUTAMOL; TERBUTALINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DISEASE EXACERBATION; DISEASE FREE INTERVAL; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FEMALE; GERMANY; HEALTH CARE COST; HEALTH PRACTITIONER; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MODERATE PERSISTENT ASTHMA; MULTICENTER STUDY; NETHERLANDS; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AGED; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HEALTH CARE COSTS; HUMANS; MIDDLE AGED;

EID: 33344469686     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.09.032     Document Type: Article

References (31)

1. M. Masoli D. Fabian S. Holt R. Beasley Global Initiative for Asthma (GINA) Program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report Allergy 59 2004 469-478
2. S. Stock M. Redaelli M. Luengen G. Wendland D. Civello K.W. Lauterbach Asthma: Prevalence and cost of illness Eur Respir J 25 2005 47-53
3. K.B. Weiss S.D. Sullivan C.S. Lyttle Trends in the cost of illness for asthma in the United States, 1985-1994 J Allergy Clin Immunol 106 2000 493-499
4. E. Van Ganse L. Laforest G. Pietri et. al. Persistent asthma: Disease control, resource utilisation and direct costs Eur Respir J 20 2002 260-267
5. F. Gallefoss P.S. Bakke Cost-effectiveness of self-management in asthmatics: A 1-yr follow-up randomized, controlled trial Eur Respir J 17 2001 206-213
6. E.D. Bateman Using clinical measures of disease control to reduce the burden of asthma Pharmacoeconomics 19 suppl 2 2001 7-12
7. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: WHO/NHLBI Workshop report. National Institutes of Health, National Heart, Lung and Blood Institute. Publication Number 02-3659, 2002.
8. R.A. Pauwels C.G. Löfdahl D.S. Postma et. al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group N Engl J Med 337 1997 1405-1411
9. P.M. O'Byrne P.J. Barnes R. Rodriguez-Roisin et. al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial Am J Respir Crit Care Med 164 2001 1392-1397
10. McCarthy TP, Rice L, Blair CA. Improved compliance with asthma therapy in children treated with salmeterol/fluticasone propionate combination (SFC) compared with concurrent salmeterol (S) plus inhaled corticosteroid (ICS) or ICS alone. Poster presented at ATS 2003, Seattle, USA. Poster no. C26.
11. C. Jones N.C. Santanello S.J. Boccuzzi J. Wogen P. Strub L.M. Nelsen Adherence to prescribed treatment for asthma: Evidence from pharmacy benefits data J Asthma 40 2003 93-101
12. F. Andersson E. Ståhl P.J. Barnes et. al. Adding formoterol to budesonide in moderate asthma - health economic results from the FACET study Respir Med 95 2001 505-512
13. B.G. Jönsson F.E. Berggren K. Svensson P.M. O'Byrne Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide-a cost-effectiveness analysis Eur Respir J 18 suppl 33 2001 517s
14. E.D. Bateman T.A. Bantje M. Joao Gomes et. al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma Am J Respir Med 2 2003 275-281
15. M.J. Sculpher M.J. Buxton The episode-free day as a composite measure of effectiveness: An illustrative economic evaluation of formoterol versus salbutamol in asthma therapy Pharmacoeconomics 4 1993 345-352
16. M.P. Rutten-van Mölken E.K. van Doorslaer R.C. van Vliet Statistical analysis of cost outcomes in a randomised controlled clinical trial Health Econ 3 1994 333-345
17. Rote Liste 2000. Aulendorf: Editio Cantor Verlag GmbH, 2000.
18. Z-Index Taxe G-Standaard, May 2001.
19. Daten des Gesundheitswesens-Ausgabe 1999. Baden-Baden: Nomos, 1999.
20. Manual for cost research Methods and recommended prices for economic evaluations in healthcare 2000 Council for Health Insurances Amstelveen (The Netherlands)
21. KV Niedersachsen, personal communication, 2000.
22. ABDA-Bundesvereinigung Deutscher Apothekerverbände, personal communication, 2000.
23. Statistisches Jahrbuch 2000 für die Bundesrepublik Deutschland. Weisbaden: Statistisches Bundesamt, 2000.
24. HStatistics Netherlands, 2000. Available from: URL: http://www.cbs.nl/en/figures/keyfigures/sip_410z.htm (2000-12-14).
25. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Guide for costing research, methods and standard costing prices for economic assessments in healthcare. Healthcare Insurance Board. Amstelveen. Updated version 2004.
26. E. Ståhl Respiratory Patients Opinion Survey (RESPONSE): Market research from asthma subjects in Europe Am J Respir Crit Care Med 165 2002 A105
27. L. Rosenhall S. Borg F. Andersson K. Ericsson Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months Int J Clin Pract 57 2003 662-667
28. G. Johansson M.J. Price S. Sondhi Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100 μg vs fluticasone propionate 100 μg in adults and adolescents with asthma. III: Results Pharmacoeconomics 16 suppl 2 1999 15-21
29. M. Palmqvist M.J. Price S. Sondhi Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250 μg vs fluticasone propionate 250 μg in adults and adolescents with asthma. IV: Results Pharmacoeconomics 16 suppl 2 1999 23-28
30. W.R. Pieters B. Lundbäck S. Sondhi M.J. Price R.M.A. Thwaites Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/500 μg vs fluticasone propionate 500 μg in patients with corticosteroid-dependent asthma. V: Results Pharmacoeconomics 16 suppl. 2 1999 29-34
31. M.J. Price A.H. Briggs Development of an economic model to assess the cost effectiveness of asthma management strategies Pharmacoeconomics 20 2002 183-194